toxylact: a06ab09 bisoxatin

The first professional lActological database in the word

Bisoxatin (ATC A06AB09) is a stimulant contact laxative used for short‑term relief of constipation and bowel preparation; based on its pharmacology and low systemic exposure, occasional use in breastfeeding is likely compatible with appropriate precautions.medpedia.framar+6

ATC class A06AB09 overview

A06AB09 designates bisoxatin within the ATC group of contact (stimulant) laxatives acting on the gastrointestinal tract.atcddd.fhi+4
Contact laxatives increase intestinal motility and fluid secretion through direct action on the colonic mucosa or enteric nerves, leading to accelerated transit and softened stools.drugbank+3
They are indicated for short‑term treatment of constipation and for bowel cleansing before diagnostic or surgical procedures when mechanical obstruction is excluded.kegg+5

Pharmacology and toxicology

Bisoxatin is a small‑molecule stimulant laxative that enhances colonic peristalsis and inhibits absorption of water and electrolytes, increasing luminal water content.pubchem.ncbi.nlm.nih+3
After oral administration, systemic absorption is limited and the primary action is local in the intestine, which generally reduces systemic toxicity compared with more extensively absorbed drugs.sps+4
Typical adverse effects reflect its pharmacodynamic profile and include abdominal cramps, diarrhea, and potential electrolyte disturbances with excessive or prolonged use.pmc.ncbi.nlm.nih+3

Rare but clinically important toxicological concerns with stimulant laxatives as a class include dehydration, secondary renal impairment, and exacerbation of pre‑existing electrolyte imbalance, especially in vulnerable patients such as the elderly or those on diuretics.medsafe+3
Chronic misuse of stimulant laxatives has been associated with colonic atony and melanosis coli, so long‑term continuous use is discouraged.sps+2
Contraindications for bisoxatin mirror those of other contact laxatives and include intestinal obstruction, acute surgical abdominal conditions, severe inflammatory bowel disease, and hypersensitivity to the active substance or excipients.atccode+4

Use in lactation: toxicological‑lactological assessment

Evidence specific to bisoxatin in human breast milk is lacking, but extrapolation can be made from its low systemic absorption, small typical oral doses, and data on laxative use in breastfeeding.ncbi.nlm.nih+5
Guidance from specialist breastfeeding resources indicates that most laxatives, particularly those with minimal systemic absorption or short courses of use, result in negligible milk transfer and are generally compatible with breastfeeding.gpnotebook+4
For poorly absorbed stimulant laxatives, infant exposure via milk is expected to be very low, although direct gastrointestinal effects (loose stools, mild diarrhea) in the infant remain a theoretical risk.pmc.ncbi.nlm.nih+3

Preferred first‑line options in breastfeeding are non‑absorbed or bulk‑forming laxatives (e.g. fiber‑based agents), but a short course of a stimulant laxative like bisoxatin may be acceptable when these are ineffective or unsuitable.medsafe+3
Use should follow general lactation safety principles: lowest effective dose, shortest duration, and timing doses after a feed to minimize peak milk concentrations.psychopharmacologyinstitute+3
Breastfed infants should be observed for changes in stool frequency or consistency, irritability, or poor weight gain, and bisoxatin should be avoided or used with particular caution in premature or medically fragile infants.pubmed.ncbi.nlm.nih+4

Clinical recommendations for breastfeeding mothers

When a breastfeeding mother requires pharmacological treatment for constipation, non‑pharmacological measures (fluids, dietary fiber, physical activity) and non‑absorbed laxatives should be optimized before considering bisoxatin.gpnotebook+3
If bisoxatin (A06AB09) is selected, it should be reserved for short‑term use, avoiding chronic administration and high doses, with clear counseling on possible maternal gastrointestinal side effects.drugs.ncats+4
Clinicians should document the indication, dose, timing relative to feeds, and infant monitoring plan, and reassess therapy promptly if the infant develops diarrhea or other concerning symptoms.pubmed.ncbi.nlm.nih+4

Summary lactation safety categorization (expert‑style)

·        Likely compatibility: Occasional, short‑term use in healthy term infants, with monitoring.ncbi.nlm.nih+4

·        Prefer alternatives: Use fiber or osmotic agents first when feasible.sps+3

·        Avoid or specialist advice: Premature infants, significant neonatal comorbidity, or maternal need for prolonged stimulant‑laxative therapy.pmc.ncbi.nlm.nih+4

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.